Scientific Programme

The 'International Osteoporosis Foundation (IOF)' (or) 'IOF Regionals 5th Asia-Pacific Osteoporosis Meeting' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS),

The 'IOF Regionals 5th Asia-Pacific Osteoporosis Meeting' is designated for a maximum of (or 'for up to') 14 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Local CME Accreditation

The following local medical associations will offer CME credits:

  • Taiwan Society of Internal Medicine      
  • Taiwan Association of Obstetrics and Gynecology      
  • Taiwan Surgical Association
  • Taiwan Association of Family Medicine
  • Taiwan Neurospinal Society
  • Endocrine Society & Diabetic Association of the Republic of China (Taiwan)
  • Taiwan Association of Gerontology and Geriatrics
  • Taiwan Rheumatology Association
  • Taiwan Orthopaedic Association  

Conflict of interest disclosure (PDF 2.3 MB)

Final Programme

Download the Programme Summary (PDF 113 KB) and Venue Map (PDF 203 KB)

(as of September 8, 2014 • Subject to change)

Friday November 14, 2014
11:00-12:15 Plenary Session I – Epidemiology
Chairs: S Ferrari (CHE) & RS Yang (TWN)
  • Welcome Address
  • Osteoporosis and Burden of Fragility Fractures in Asia
    KE Huang (TWN)
  • FRAX® Uptake in Asia and Worldwide
    JA Kanis (UK)
  • Mobile DXA in Asia-Pacific Epidemiology Survey
    BT Kin (KOR)
12:30-13:30 Lunch Industry-sponsored Symposium
13:30-14:00 Coffee Break
14:00-15:30 Plenary Session II – Osteoporosis in Men
Chairs: P Ebeling (AUS) & DC Chan (TWN)
  • Osteoporosis in Men: What is Mr Os telling us?
    E Orwoll (USA)
  • Sex-specific and Race Difference in Skeletal Fragility
    E Seeman (AUS)
  • Nutrition and Risk of Hip Fracture in Men: The Singapore Chinese health study
    WP Koh (SGP)
  • OC1 – Randomized Controlled Trial to Assess the Safety and Efficacy of Odanacatib in the Treatment of Men with
    Osteoporosis – E Orwoll*, S Adami, N Binkley,
    R Chapurlat, B Langdahl, S Doleckyj, H Giezek, BB Scott, A Santora
  • OC2 – Capture the Fracture: A worldwide initiative for the secondary prevention of osteoporotic fracture –
    MK Javaid, C Kyer, PJ Mitchell, C Moss, A McLellan, 
  • J Stenmark, DD Pierroz, K Akesson, C Cooper*
  • OC3 – The Relative Weight of Risk Factor in FRAX® Tool in Taiwan is Different from Other Populations – CY Hsu*, JF Chen, WC Chiu, SF Yu, TT Cheng
15:30-16:00 Break
16:00-17:30 Plenary Session III – Muscle Function and Bone Fragility
Chairs: A Mithal (IND) & FP Chen (TWN)
  • Epidemiology of Sarcopenia in Asia-Pacific
    LK Chen (TWN)
  • Development of Therapeutic Strategies for Muscle Wasting
    G Krishnan (USA)
  • Physical Exercise: What, when and how
    R Daly (AUS)
  • Fragility and Fracture Risk in Japan
    S Ogawa (JPN)
17:30-18:30 Opening Ceremony
18:30-20:00 Welcome Reception & Exhibition


Saturday November 15, 2014
08:00-09:00 Meet-The-Expert Session I
  • Prediction of Fracture Risk
    JA Kanis (UK)
  • Alternatives to Bisphosphonates Treatment for Postmenopausal Osteoporosis
    JK Lee (MLY)
  • Vitamin D Status in Asia-Pacific
    A Mithal (IND)
  • New Insight on the Cardiovascular Safety of Strontium Ranelate
    JY Reginster (BEL)
  • Bariatric Surgery and Bone
    M Chandran (SGP)
09:00-10:30 Plenary Session IV – Bone and Diabetes
Chair: KE Huang (TWN), C Cooper (UK)
  • Welcome Address
    PQ Chen (TWN)
  • How Diabetes affects Bone
    S Ferrari (CHE)
  • Epidemiology of Diabetes and its Impact on Bone and Fractures
    JF Chen (TWN)
  • Anti-diabetic Drug Effects on Bone
    M Chandran (SGP)
  • Oral Abstracts
  • OC4 – Effects of Denosumab on Bone Mineral Density in Postmenopausal Women Transitioning from Raloxifene – KT Yeh*, WT Wu, CH Thu, JH Wang
  • OC5 – Odanacatib Anti-fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from
    the phase III long-term Odanacatib fracture trial – MR McClung, B Langdahl, S Papapoulos, KG Saag,
    S Adami, HG Bone, T De Villiers, DP Kiel, A Kung, P Kumar, SK Lim, X Ling, K Lippuner, C Mautalen, T Nakamura, JY Reginster, IR Reid*, JA Rodriguez-Portales, C Roux, J Walliser, NB Watts, J Zanchetta, CAF Zerbini, A Rybak-Feiglin, D Cohn, CA DaSilva, R Massaad, A Santora, BB Scott, N Verbuggen, A Leung, A Lombardi
  • OC6 – Relationship Between FRAX® Score and Falls in Community-dwelling Middle-aged and Old People –
    LC Ou*, CS Chang, YF Chang, TH Chao, RM Lin, ZJ Sun, CH Wu
10:30-11:15 Poster Session I (P100-P142, P144-P165, P205) & Exhibition
11:15-12:45 Plenary Session V: What’s new in skeletal therapies?
Chairs: E Seeman (AUS) & JK Lee (MLY)
  • An Update on SERM for the Prevention and Treatment of Osteoporosis
    FP Chen (TWN)
  • Mechanisms of Action and Effects of Cathepsin K Inhibitors
    S Ferrari (CHE)
  • Mechanisms of Action and Effects of Sclerostin Antibodies
    KS Tsai (TWN)
  • Structural Management of Osteoarthritis: Fact or fantasy
    JY Reginster (BEL)
13:00-14:00 Lunch Industry-sponsored Symposium
14:00-14:45 Coffee Break

IOF Young Investigator Award Session
Chairs: R. Rizzoli (CHE) and H. Orimo (JPN)

  • OC7 – Quantification of the Heterogeneity of Cortical Porosity and the Effect on Strength – A Zendeli*, Y Bala,
  • M Kersh, A Gashem-Zadeh, E Seeman, R Zebaze
  • OC8 – Sedentary Time Negates the Positive Influence of Moderate-to-vigorous Physical Activity but not Vigorous
  • Physical Activity on Bone Strength in Adolescent Girls – VPS Tan*, HM Macdonald, HA McKay
  • OC9 – Projection of Incidence and Economic Burden of Osteoporosis-related Fractures in China: 2010-2050 –
  • L Si*, T Winzenberg, Q Jiang, M Chen, A Palmer
  • OC10 – Association Between Body Weight Change and Risk of Hip Fracture Among Singapore Chinese – Z Dai*, LW Ang, WP Koh
  • OC11 – Early Hip Fracture Surgery reduces One-year Mortality and improves Long-term Survival in Southern Chinese – Y Yip Kan*, SH Wong, AW H Ho, ST Ho
15:45-16:30 Poster Viewing & Exhibition
16:30–18:00 Plenary Session VI – Secondary Fracture Prevention
Chairs: R Daly (AUS) & S Ogawa (JPN)
  • Capture the Fracture: Overview
    C Cooper (UK)
  • Orthopaedic Trends in Major Osteoporotic Fractures
    S Bavonratanavech (THA)
  • Fracture Liaison Services in Asia Pacific:
    -Chinese Taipei, D-C Chan
    -Singapore, M Chandran
    -Japan, H Hagino
    -Malaysia, J-K Lee
    -Australia, P Ebeling
    -China, T Sun


Sunday November 16, 2014
08:00-09:00 Meet-The-Expert Session II
  • Atypical Femoral Fracture
    RS Yang (TWN)
  • Calcium, Vitamin D and Antiepileptic Drugs
    SC Shin (KOR)
  • Green Tea Polyphenols for Bone Health
    CH Wu (TWN)
  • Guidelines for GIO 
    C Cooper (UK)
  • Sarcopenia
    R Rizzoli (CHE)
09:00-10:30 Plenary Session VII
Chairs: KS Tsai (TWN) & S Vasikaran (AUS)
  • Welcome Address
    TS Yang (TWN)
  • Best Clinical Papers in 2014
    R Rizzoli (CHE)
  • OC12 – Celiac Disease and Low Femoral Bone Density in a Multiethnic US National Survey – Y Shen*, M. Wang, D. Martinez
  • OC13 – Morbidity as a Risk Factor for Falls in Early Postmenopausal Women According to Type of Fall – N Afrin*, H Koivumaa-Honkanen, T Rikkonen, H Kröger, R Honkanen
  • OC14 – PQCT Predicted Non-vertebral Fracture in Older Non-osteoporotic Men Independently of DXA – T Kwok*
  • OC15 – The Neglected Health Burden of Non-hip/wrist/vertebral Fracture (AusICUROS) – KM Sanders*, J Abimanyi-Ochom, JJ Watts, GC Nicholson, C Shore-Lorenti, AL Stuart, Y Zhang, S Iluiano, E Seeman, R Prince, L March, M Cross, T Winzenberg, LL Laslett, G Duque, PR Ebeling, F Borgstrom
  • OC16 – Inhibition of P38 MAPK-regulated Pathway Reinforces Treatment Effect of Bisphosphonate – TW Tai*, CY Chen, CF Lin, IM Jou
  • OC17 – Effect of Osteophytosis at the Knee on Health-related Quality of Life. A 3-year Follow-up of the ROAD Study – S Muraki*, T Akune, S Tanaka, H Kawaguchi, K Nakamura, H Oka, N Yoshimura
10:30-11:15 Poster Session II (P143, P166-P204, P206-P232) & Exhibition
11:15-12:45 Plenary Session VIII – What’s new in skeletal assessment?
Chairs: S Ferrari (CHE) & LK Chen (TWN)
  • Assessment of Cortical Porosity
    R Zebaze (AUS)
  • Microstructure Analysis of Bone Strength
    M Ito (JPN)
  • What is new in Imaging for Fracture Prediction
    P Ebeling (AUS)
  • Markers of Bone Turnover: What are their clinical uses? S Vasikaran (AUS)
13:00-14:00 Lunch Industry-sponsored Symposium
14:00-14:45 Coffee Break
14:45-16:15 Plenary Session IX: Nutritients & environmental factors
Chairs: S. Takeda (JPN) & SC Shin (KR)
  • Effects of Balance Exercises on Muscle Strength and Bone in Community-living Elderly People
    WL Hsu (TWN)
  • Dairy and Non-dairy Calcium Effects on Bone
    R Rizzoli (CHE)
  • Implication of Vitamin E in Bone Metabolism
    S Takeda (JPN)
  • Community-based Programme
    KH Hsu (TWN)
  • Closing Remarks


Key themes

(as of December 2013 • Subject to change)

  • Epidemiology of Osteoporosis and burden in Asia
  • Osteoporosis in men
  • Secondary fracture prevention
  • Muscle biology &  clinical fragility
  • Bone and Diabetes
  • Horizon therapy

Hot Topics

(In Plenary, Oral Communication & Meet-the-Expert Sessions - with direct clinical relevance for a broad audience)

  • FRAX Uptake in Asia and worldwide
  • Development of therapeutic strategies for muscle wasting
  • Bone quality in diabetes
  • Bone mass in children with Type 1 Diabetes
  • Osteoporosis in men: What are the specificities
  • Sex-specific difference in skeletal fragility
  • Menopausal hormone therapy: 10 years after Women’s Health Initiative, where are we?
  • Novel antiresorptive therapy
  • Sclerostin, the new anabolic agent
  • Capture the fracture – updates
  • Bariatric surgery and bone